top of page
About Us

About Us

The team at HaemaLogiX, together with our collaborators, is researching unique immune-based treatments to improve outcomes in patients suffering from blood cancers. The goal of these treatments is to help a patient’s immune system fight their own disease. We aim to commercialise our therapies through a series of strategic partnerships.

HaemaLogiX was formed as a private Australian biotech company in late 2014. Soon after, we acquired the core proprietary technologies that are the foci of our research and development efforts to treat multiple myeloma. Multiple myeloma is a haematological (blood) cancer of plasma cells (B cells) that can cause focused damage to a patient’s bone marrow. Multiple Myeloma is considered treatable but generally incurable.

Since inception, our research and development activities have been funded by a small group of largely Australian investors, together with the four directors who jointly own a majority share.

The HaemaLogiX team has a wide range and depth of experience in antibody research, nonclinical & clinical development, manufacturing and commercialisation. Our Scientific Advisory Board (SAB) members are internationally recognised experts in monoclonal antibodies and haematology. Our current research and clinical trial partners are global leaders in Multiple Myeloma and AL Amyloidosis therapy.

Executive Team

Management Team

New Headshot 1.jpg
HLX circ.png

Damian Clarke-Bruce

Managing Director |

Chief Executive Officer

rosanne.jpg
HLX circ.png

Dr. Rosanne Dunn

Director |

Chief  Scientific Officer

professor.jpg
HLX circ.png

Prof. Mohamad Hussein

Chief Medical Advisor

Tertia_small.png
HLX circ.png

Tertia Dex

Chief  Manufacturing  &

Development Officer

Z6P_1155-2_edited_edited.jpg
HLX circ.png

Dr Ben Buckley, PHD

Principal Scientist

Scientific Advisory Board

rhonda.jpg
HLX circ.png

Rhonda Oshanek

Principal Medical Writer

paul.jpg
HLX circ.png

Professor 

Paul Richardson

005_Andrew Spencer_20230405_edited.png
HLX circ.png

Professor 

Andrew Spencer

Board of Directors

SJ Headshot Round.jpg
HLX circ.png

Professor 

Simon Harrison

david.jpg
HLX circ.png

Professor 

David Gottlieb

bryce.jpg
HLX circ.png

Bryce Carmine

Non-Executive Director 

allan.jpg
HLX circ.png

Alan Liddle

Non-Executive Officer

JC circle.jpg
HLX circ.png

Dr. John Cullity

Chairman

New Headshot 1.jpg
HLX circ.png

Damian Clarke-Bruce

Managing Director |

Chief Executive Officer

rosanne.jpg
HLX circ.png

Dr. Rosanne Dunn

Director |

Chief  Scientific Officer

AxDphoto1 (002)_edited.png
HLX circ.png

Angela

Dispenzieri, M.D. 

jesus.jpg
HLX circ.png

Professor 

Jesus San-Miguel

Home_Leadership_Laurence Turka_large_A.jpg
HLX circ.png

Dr. Laurence Turka

Non-Executive Director

Halley_circle_Jan22.png
HLX circ.png

Halley Hilton

Director, Clinical Operations

Kerem Kaya_edited.jpg
HLX circ.png

Kerem Kaya

Company  Secretary  |

Chief  Financial Officer

Professor The Honourable Greg Hunt_Hi Res_edited.jpg
HLX circ.png

Professor the Hon Greg Hunt

Non-Executive Director 

Scientific Advisory Board
Board of Directors
bottom of page